Literature DB >> 11696634

On measuring hypoxia in individual tumors with radiolabeled agents.

J D Chapman1, P Zanzonico, C C Ling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11696634

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  9 in total

1.  The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake.

Authors:  Cameron J Koch; Anne L Shuman; Walter T Jenkins; Alexander V Kachur; Joel S Karp; Richard Freifelder; William R Dolbier; Sydney M Evans
Journal:  Int J Radiat Biol       Date:  2009-12       Impact factor: 2.694

2.  Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.

Authors:  Cameron J Koch; Joshua S Scheuermann; Chaitanya Divgi; Kevin D Judy; Alexander V Kachur; Richard Freifelder; Janet S Reddin; Joel Karp; James B Stubbs; Stephen M Hahn; Jason Driesbaugh; Deborah Smith; Susan Prendergast; Sydney M Evans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-29       Impact factor: 9.236

3.  Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET.

Authors:  Kelin Wang; Ellen Yorke; Sadek A Nehmeh; John L Humm; C Clifton Ling
Journal:  Med Phys       Date:  2009-10       Impact factor: 4.071

4.  A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia.

Authors:  Bixiu Wen; Paul Burgman; Pat Zanzonico; Joseph O'donoghue; Shangde Cai; Ron Finn; Inna Serganova; Ronald Blasberg; Juri Gelovani; Gloria C Li; C Clifton Ling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-16       Impact factor: 9.236

5.  Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.

Authors:  P Mahy; X Geets; M Lonneux; P Levêque; N Christian; M De Bast; J Gillart; D Labar; J Lee; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-04       Impact factor: 9.236

6.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.

Authors:  Nancy Y Lee; James G Mechalakos; Sadek Nehmeh; Zhixiong Lin; Olivia D Squire; Shangde Cai; Kelvin Chan; Pasquale B Zanzonico; Carlo Greco; Clifton C Ling; John L Humm; Heiko Schöder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

7.  Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Authors:  Florian C Maier; Manfred Kneilling; Gerald Reischl; Funda Cay; Daniel Bukala; Andreas Schmid; Martin S Judenhofer; Martin Röcken; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  Radiat Oncol       Date:  2011-11-25       Impact factor: 3.481

8.  Positron emission tomography detection of human endothelial cell and fibroblast monolayers: effect of pretreament and cell density on 18FDG uptake.

Authors:  Julie A Chouinard; Jacques A Rousseau; Jean-François Beaudoin; Patrick Vermette; Roger Lecomte
Journal:  Vasc Cell       Date:  2012-03-20

9.  Beyond FDG: novel PET tracers for cancer imaging.

Authors:  Rodney J Hicks
Journal:  Cancer Imaging       Date:  2003-09-02       Impact factor: 3.909
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.